363 related articles for article (PubMed ID: 22496812)
1. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
Redmond WL; Triplett T; Floyd K; Weinberg AD
PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
[TBL] [Abstract][Full Text] [Related]
2. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
Redmond WL; Gough MJ; Weinberg AD
Eur J Immunol; 2009 Aug; 39(8):2184-94. PubMed ID: 19672905
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
4. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
[TBL] [Abstract][Full Text] [Related]
5. Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8
Amani MF; Rolig AS; Redmond WL
J Immunol; 2020 Oct; 205(7):1857-1866. PubMed ID: 32848035
[TBL] [Abstract][Full Text] [Related]
6. A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors.
Konstorum A; Vella AT; Adler AJ; Laubenbacher RC
Sci Rep; 2019 Jul; 9(1):10862. PubMed ID: 31350431
[TBL] [Abstract][Full Text] [Related]
7. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
[TBL] [Abstract][Full Text] [Related]
8. Time-Dependent Regulation of IL-2R α-Chain (CD25) Expression by TCR Signal Strength and IL-2-Induced STAT5 Signaling in Activated Human Blood T Lymphocytes.
Shatrova AN; Mityushova EV; Vassilieva IO; Aksenov ND; Zenin VV; Nikolsky NN; Marakhova II
PLoS One; 2016; 11(12):e0167215. PubMed ID: 27936140
[TBL] [Abstract][Full Text] [Related]
9. Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells.
So T; Croft M
J Immunol; 2007 Aug; 179(3):1427-30. PubMed ID: 17641007
[TBL] [Abstract][Full Text] [Related]
10. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
12. A dynamic dual role of IL-2 signaling in the two-step differentiation process of adaptive regulatory T cells.
Guo Z; Khattar M; Schroder PM; Miyahara Y; Wang G; He X; Chen W; Stepkowski SM
J Immunol; 2013 Apr; 190(7):3153-62. PubMed ID: 23427250
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.
Mittal P; St Rose MC; Wang X; Ryan JM; Wasser JS; Vella AT; Adler AJ
J Immunol; 2015 Dec; 195(12):5816-26. PubMed ID: 26561553
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
15. A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions.
Lathrop SK; Huddleston CA; Dullforce PA; Montfort MJ; Weinberg AD; Parker DC
J Immunol; 2004 Jun; 172(11):6735-43. PubMed ID: 15153490
[TBL] [Abstract][Full Text] [Related]
16. Exogenous OX40 stimulation during lymphocytic choriomeningitis virus infection impairs follicular Th cell differentiation and diverts CD4 T cells into the effector lineage by upregulating Blimp-1.
Boettler T; Choi YS; Salek-Ardakani S; Cheng Y; Moeckel F; Croft M; Crotty S; von Herrath M
J Immunol; 2013 Nov; 191(10):5026-35. PubMed ID: 24101548
[TBL] [Abstract][Full Text] [Related]
17. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
[TBL] [Abstract][Full Text] [Related]
18. IL-12 is required for anti-OX40-mediated CD4 T cell survival.
Ruby CE; Montler R; Zheng R; Shu S; Weinberg AD
J Immunol; 2008 Feb; 180(4):2140-8. PubMed ID: 18250420
[TBL] [Abstract][Full Text] [Related]
19. The role of OX40-mediated co-stimulation in T-cell activation and survival.
Redmond WL; Ruby CE; Weinberg AD
Crit Rev Immunol; 2009; 29(3):187-201. PubMed ID: 19538134
[TBL] [Abstract][Full Text] [Related]
20. STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors.
Verdeil G; Puthier D; Nguyen C; Schmitt-Verhulst AM; Auphan-Anezin N
J Immunol; 2006 Apr; 176(8):4834-42. PubMed ID: 16585578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
